Skip to content
Boost Up Blog – Lifestyle
Author:
Pliant Therapeutics, Inc.
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
August 18, 2026
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 11, 2026
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
July 13, 2026
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 22, 2026
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 20, 2026
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
May 6, 2026
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
April 30, 2026
Adient Introduces ProForce Massage Flow Solution
April 26, 2026
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
April 18, 2026
Adient launches StepJoy foot massage innovation
April 10, 2026
1
2
Next Page
→